Electromed(ELMD) - 2026 Q2 - Quarterly Report

Financial Performance - Net revenues for the three months ended December 31, 2025, increased by $2,642,000, or 16.3%, to $18,897,000 compared to the same period in the prior year[61] - Homecare revenue increased by $2,681,000, or 18.4%, for the three months ended December 31, 2025, driven by an increase in direct sales representatives[62] - Gross profit for the three months ended December 31, 2025, increased to $14,819,000, or 78.4% of net revenues, compared to $12,627,000, or 77.7% in the prior year[66] - Operating income increased by $1,078,000, or 42.4%, to $3,620,000, or 19.2% of net revenues, for the three months ended December 31, 2025[74] - Net income for the three months ended December 31, 2025, was $2,761,000, representing an increase of 40.3% compared to $1,968,000 for the same period in the prior year[78] Expenses - Research and development expenses increased by $133,000, or 53.0%, for the three months ended December 31, 2025, primarily due to increased headcount and consulting expenses[73] - Selling, general and administrative expenses increased by $981,000, or 10.0%, for the three months ended December 31, 2025, compared to the same period in the prior year[67] Cash Flow and Investments - Cash flows from operating activities for the six months ended December 31, 2025, were $3,195,000, consisting of net income of $4,897,000 and non-cash expenses of $1,631,000[79] - Cash used for investing activities for the six months ended December 31, 2025, was $923,000, primarily for property and equipment[80] - Cash used for financing activities for the six months ended December 31, 2025, was $3,768,000, mainly for the share repurchase program[81] - For the six months ended December 31, 2025, the company spent approximately $886,000 on property and equipment, compared to $270,000 for the same period in 2024[86] Credit and Financing - The company maintains a $10,000,000 revolving line of credit with an interest rate of 3.87% plus 1.75% as of December 31, 2025[83] - The company expects to finance planned equipment purchases with cash flows from operations or borrowings under the credit facility[86] - The company believes its cash, cash equivalents, and cash flows from operations will be sufficient to meet working capital and capital expenditure requirements for fiscal 2026[87] - The credit facility includes covenants such as a maximum total funded debt ratio of 2.50x and a minimum fixed charge coverage ratio of 1.20x[84] - Any failure to comply with the covenants may result in an event of default, potentially leading to accelerated maturity of indebtedness[85] - The company has no outstanding principal balance on the line of credit as of December 31, 2025[83] - The company may need to incur additional debt if unforeseen capital equipment needs arise or if operating performance does not generate adequate cash flow[86] Risks - The company faces risks including reimbursement from Medicare and Medicaid, component shortages, and regulatory compliance[90] - The company is evaluating projected expenditures relative to available cash and financing alternatives to meet cash requirements[87]